Versatope Therapeutics is pioneering the use of Recombinant Extracellular Transport Vesicles (RET-Vs) as a versatile biotechnology platform for vaccine and therapeutic delivery. These designer vesicles, derived from genetically engineered probiotics, are capable of transporting a variety of biochemicals, including nucleic acids and peptides, to specifically modify the activity of target cells. By engineering the surface of these vesicles to display multiple viral variants, Versatope aims to create more effective vaccines that confer cross-strain immunity, particularly against infectious diseases like influenza and targeted RNA therapeutics for cancer. This innovative approach allows for long-term immunity and the potential for time-release formulations, reducing the frequency of vaccine administrations.

One of the company's notable advancements is the development of a universal influenza vaccine candidate, VT-105, which has shown promise in preclinical studies for providing robust immunity against multiple strains of the virus. Unlike traditional vaccines that must be updated annually due to the rapidly changing nature of the influenza virus, Versatope's RET-Vs can present proteins from various strains on a single nano-vesicle, enhancing the vaccine's effectiveness. This technology not only addresses the limitations of current influenza vaccines but also positions Versatope at the forefront of immunotherapy for both infectious diseases and cancer, with ongoing efforts to scale up their vaccine candidate for regulatory approval.

United States

Versatope Therapeutics is an infectious disease company with two lead development programs and others at the preclinical stage. Versatope delivers immunity by customizing nano-size vesicles by using synthetic biology for biopharmaceutical applications.

Versatope Therapeutics

Company Details